Nimotuzumab
- Generic Name
- Nimotuzumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 780758-10-3
- Unique Ingredient Identifier
- 6NS400BXKH
- Indication
Investigated for use/treatment in head and neck cancer, brain cancer, pediatric indications, pancreatic cancer, lung cancer, and colorectal cancer.
- Associated Conditions
- Advanced Head and Neck Cancer, Advanced Stage Head and Neck Cancer, Glioblastoma Multiforme (GBM), High Grade Glioma (HGG), Advanced Epithelial Tumor of the Head and Neck
- Associated Therapies
- -
Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- Hui Bu
- Target Recruit Count
- 30
- Registration Number
- NCT04833205
- Locations
- 🇨🇳
The Second Hospital of Hebei Medical University, Hebei, China
Neoadjuvant Treatment Modalities in Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-03-30
- Last Posted Date
- 2023-11-24
- Target Recruit Count
- 2000
- Registration Number
- NCT04821843
- Locations
- 🇨🇳
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China
Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-03-30
- Last Posted Date
- 2024-12-13
- Target Recruit Count
- 2000
- Registration Number
- NCT04821778
- Locations
- 🇨🇳
Department 4th of Radiation Oncology, Anyang Cancer Hospital, Anyang, Henan, China
🇨🇳Department of Radiation oncology, Jiangsu Province Hospital/The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
🇨🇳Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China
Nimotuzumab Combined With Chemoradiotherapy Versus Chemoradiotherapy for Local Advanced Cervical Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-12-22
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 286
- Registration Number
- NCT04678791
- Locations
- 🇨🇳
Peking University 3rd Hospital, Beijing, Beijng, China
TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-07-17
- Last Posted Date
- 2022-06-09
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 29
- Registration Number
- NCT04475016
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Xin-Hua Xu
- Target Recruit Count
- 68
- Registration Number
- NCT04367909
- Locations
- 🇨🇳
Department of Medical Oncology, Central Hospital of Yichang City, the First Clinical Medical College of Three Gorges University, Yichang, Hubei, China
A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-12-23
- Last Posted Date
- 2024-05-16
- Target Recruit Count
- 55
- Registration Number
- NCT04207918
- Locations
- 🇨🇳
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China
Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2021-01-29
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 47
- Registration Number
- NCT03915132
- Locations
- 🇨🇳
Cancer hospital, Chinese Academy of Medical Sciences, Beijin, China
Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-02-12
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 384
- Registration Number
- NCT03837808
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Nimotuzumab for Recurrent Nasopharyngeal Carcinoma
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2018-09-11
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 67
- Registration Number
- NCT03666221
- Locations
- 🇨🇳
Department of radiation oncology, Fujian cancer hospital, Fuzhou, Fujian, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.